TCL Archive Avastin Phase III Trial Meets Endpoint: PFS in Platinum-Sensitive Ovarian Cancer February 25, 2011
TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004
TCL Archive Two-Year Remission While Taking Gleevec Puts Patients Into Normal Mortality Rate March 25, 2011
TCL Archive In Brief: Bristol Has Change Of Heart, Agrees To Supply NCI With VP-16 Free For Group C Distribution July 16, 1982
